Mitsubishi Tanabe Pharma

Stelic Institute & Co., Inc. is a Tokyo-based company founded in 2004 that specializes in the research and development of clinical therapies targeting fibrosis and cancer. The organization focuses on drug development activities that encompass clinical research in the fields of biotechnology and life sciences. As of February 28, 2018, Stelic Institute operates as a subsidiary of Mitsubishi Tanabe Pharma Corporation, reinforcing its commitment to advancing innovative treatment solutions in these critical areas of healthcare.

NeuroDerm Ltd. is a clinical-stage pharmaceutical company based in Rehovot, Israel, focused on developing innovative drug-device combinations for the treatment of central nervous system (CNS) disorders. Established in 2003, the company has advanced several product candidates through clinical trials, including ND0612L and ND0612H, which are designed for patients with moderate to advanced Parkinson’s disease and have completed Phase IIa trials. Additionally, NeuroDerm is working on ND0701, a subcutaneously delivered apomorphine formulation for patients with moderate to severe Parkinson’s disease who do not respond adequately to traditional therapies. The company is also developing ND0801, currently in Phase IIa trials, aimed at addressing cognitive disorders linked to CNS diseases such as ADHD, Alzheimer’s disease, and schizophrenia. NeuroDerm's innovative approach focuses on overcoming the limitations of existing treatments to enhance clinical efficacy and improve patients' quality of life. As of October 2017, NeuroDerm operates as a subsidiary of Mitsubishi Tanabe Pharma Corporation.

Medicago Inc. is a biotechnology company headquartered in Quebec City, Canada, specializing in the research, development, and commercialization of vaccines. The company employs proprietary plant-based manufacturing and virus-like particle (VLP) technologies to create innovative vaccines and therapeutics for infectious diseases. Its notable product candidates include a VLP vaccine for the H5N1 pandemic influenza, which has successfully completed Phase I clinical trials, as well as an H1N1 VLP vaccine aimed at the Influenza A/California/04/09 virus and various seasonal influenza vaccines. Medicago has established collaboration agreements with organizations such as Viridis S.A. and Genopole biopark for the production of pandemic and seasonal influenza vaccines, alongside a partnership with Philip Morris International for developing a therapeutic protein with a human-compatible glycosylation pattern. Founded in 1997, Medicago is dedicated to addressing emerging public health challenges through its advanced vaccine technologies.

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing prescription products aimed at addressing vitamin D insufficiency and secondary hyperparathyroidism (SHPT) linked to chronic kidney disease (CKD). The company has a portfolio of innovative therapies specifically designed to safely and effectively treat patients with vitamin D deficiency and SHPT across various stages of CKD. Additionally, Cytochroma is working on novel treatments targeting elevated blood phosphorus levels, or hyperphosphatemia, to enhance the management of SHPT in CKD patients.

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing prescription products aimed at addressing vitamin D insufficiency and secondary hyperparathyroidism (SHPT) linked to chronic kidney disease (CKD). The company has a portfolio of innovative therapies specifically designed to safely and effectively treat patients with vitamin D deficiency and SHPT across various stages of CKD. Additionally, Cytochroma is working on novel treatments targeting elevated blood phosphorus levels, or hyperphosphatemia, to enhance the management of SHPT in CKD patients.